Intra-Cellular Therapies Inc (STU:23I)
€ 81.5 2 (2.52%) Market Cap: 8.63 Bil Enterprise Value: 7.68 Bil PE Ratio: 0 PB Ratio: 7.86 GF Score: 60/100

Intra-Cellular Therapies Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 16, 2020 / 06:00PM GMT
Release Date Price: €26.19 (-0.30%)
Jessica Chutter
Morgan Stanley - Chairman of Biotechnology Investment Banking

Good afternoon. This is Jessica Chutter from Morgan Stanley, and we're very pleased to be hosting the fireside chat for Intra-Cellular Therapies. And with us today, we have Sharon Mates, Chief Executive Officer; Mark Neumann, Chief Commercial Officer; and Andy Satlin, Chief Medical Officer.

Before we start, I have to read a webcast disclaimer. Please note that this webcast is for Morgan Stanley clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you are a member of the press, please disconnect and reach out separately. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representatives.

Okay. Great. Well, with that behind us, Sharon, it's obviously been a very, very exciting time for Intra-Cellular with your launch of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot